GlassScriptPhysician profile
Ronal D Legako
NPI 1356318919
$4,673.37
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $246 · 2021: $880 · 2022: $2,854 · 2023: $14.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $581.42 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $497.11 | 2022 | |
| Glaxosmithkline, LLC. | $389.45 | 2021-2022 | |
| Amarin Pharma, INC. | $327.25 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.62 | 2021-2022 | |
| Lilly USA, LLC | $225.69 | 2021-2022 | |
| Pfizer INC. | $209.82 | 2019-2022 | |
| Genentech USA, INC. | $205.51 | 2020-2022 | |
| Abbott Laboratories | $201.61 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $175.02 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $173.16 | 2021-2022 | |
| Novo Nordisk INC | $166.39 | 2019-2021 | |
| Allergan, INC. | $164.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $152.73 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $109.50 | 2021-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $97.04 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $83.61 | 2022 | |
| Astellas Pharma US INC | $69.09 | 2021-2022 | |
| Dynavax Technologies Corporation | $57.26 | 2022 | |
| Althera Pharmaceuticals LLC | $56.30 | 2022 | |
| Amgen INC. | $48.10 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $39.25 | 2021 | |
| Upsher-Smith Laboratories LLC | $38.56 | 2022 | |
| Supernus Pharmaceuticals, INC. | $27.31 | 2021-2022 | |
| Sanofi Pasteur INC. | $24.71 | 2022 | |
| Therapeuticsmd, INC. | $18.37 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.73 | 2022 | |
| Dexcom, INC. | $14.46 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.10 | 2019 | |
| Hologic Sales and Service, LLC | $13.92 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.90 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.72 | 2022 | |
| Inogen, INC. | $3.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronal Legako listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.